Korean biotech & pharma: who is buying?
Foreign, institutional and retail net flows for 120 KOSPI and KOSDAQ biotech and pharmaceutical companies, sorted by 20-session foreign net buying. Data as of Oct 13, 2026.
Summary
Over the last 20 trading sessions foreign investors net sold ₩608.4bn ($456M) of the 120 biotech and pharma stocks covered here, with net buying in 39 of them. Institutions net sold ₩358.5bn and retail investors net bought ₩836.5bn over the same window. The largest foreign purchases were Pharma Research, Alteogen, Seegene. The largest foreign sales were HLB, Sam Chun Dang Pharm, Hanmi Pharm. Foreign investors own 9.2% of the average company in this group (simple average of KRX ownership ratios).
Korean biotech is where foreign flows matter most: licensing deals with global pharma, U.S. FDA milestones and index inclusion decisions are announced in English, but the daily KRX data on who is actually buying the shares is published only in Korean. Each company below links to a page with its full flow history, foreign ownership trend and financials.
| Company | Ticker | Market | Market cap | Foreign own. | Fwd P/E | Foreign 1d | Foreign 5d | Foreign 20d | (USD 20d) | Institutions 20d | Retail 20d |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharma Research 파마리서치 | 214450 | KOSDAQ | ₩3T ($2.1B) | 14.1% | 12.0× | +₩17.1bn | +₩46.2bn | +₩130.6bn | +$98M | ₩-166.0bn | +₩38.3bn |
| Alteogen 알테오젠 | 196170 | KOSDAQ | ₩16T ($11.7B) | 15.96% | 43.3× | +₩26.0bn | +₩42.7bn | +₩114.1bn | +$86M | ₩-73.9bn | ₩-33.1bn |
| Seegene 씨젠 | 096530 | KOSDAQ | ₩2T ($1.3B) | 23.95% | 17.3× | +₩1.5bn | +₩16.1bn | +₩44.5bn | +$33M | +₩8.0bn | ₩-52.2bn |
| ABL Bio 에이비엘바이오 | 298380 | KOSDAQ | ₩2T ($1.8B) | 14.48% | 134.0× | ₩-0.1bn | ₩-13.5bn | +₩34.3bn | +$26M | ₩-53.9bn | +₩24.4bn |
| Celltrion 셀트리온 | 068270 | KOSPI | ₩42T ($31.4B) | 25.29% | 24.3× | ₩-4.8bn | ₩-11.4bn | +₩30.4bn | +$23M | ₩-81.6bn | ₩-59.5bn |
| Hanall Biopharma 한올바이오파마 | 009420 | KOSPI | ₩2T ($1.6B) | 4.46% | 2985.1× | +₩3.0bn | +₩4.7bn | +₩17.3bn | +$13M | ₩-36.8bn | +₩19.9bn |
| ST Pharm 에스티팜 | 237690 | KOSDAQ | ₩2T ($1.3B) | 13.32% | 20.8× | ₩-0.4bn | +₩3.3bn | +₩11.0bn | +$8M | ₩-9.1bn | ₩-4.6bn |
| Peptron 펩트론 | 087010 | KOSDAQ | ₩2T ($1.5B) | 4.88% | – | +₩1.8bn | +₩13.3bn | +₩9.4bn | +$7M | ₩-22.9bn | +₩13.9bn |
| Liga Chem Biosciences 리가켐바이오 | 141080 | KOSDAQ | ₩2T ($1.8B) | 12.7% | – | +₩1.9bn | ₩-7.0bn | +₩8.8bn | +$7M | ₩-57.3bn | +₩48.0bn |
| D&D Pharmatech 디앤디파마텍 | 347850 | KOSDAQ | ₩2T ($1.3B) | 10.08% | – | +₩4.2bn | ₩-8.5bn | +₩7.5bn | +$6M | ₩-19.6bn | +₩11.4bn |
| Naturecell 네이처셀 | 007390 | KOSDAQ | ₩2T ($1.1B) | 7.39% | – | +₩0.7bn | +₩0.9bn | +₩5.0bn | +$4M | ₩-0.5bn | ₩-4.5bn |
| GC Genome 지씨지놈 | 340450 | KOSDAQ | ₩0T ($0.2B) | 4.69% | 32.1× | +₩0.9bn | +₩4.1bn | +₩4.8bn | +$4M | +₩7.4bn | ₩-12.7bn |
| SK Bioscience SK바이오사이언스 | 302440 | KOSPI | ₩3T ($2.1B) | 6.11% | – | +₩1.0bn | +₩2.9bn | +₩4.7bn | +$4M | ₩-4.2bn | ₩-0.6bn |
| In Body 인바디 | 041830 | KOSDAQ | ₩1T ($0.5B) | 33.5% | 11.1× | +₩0.6bn | ₩-1.9bn | +₩4.5bn | +$3M | +₩2.7bn | ₩-7.0bn |
| Orum Therapeutics 오름테라퓨틱 | 475830 | KOSDAQ | ₩0T ($0.3B) | 7.6% | – | +₩1.5bn | +₩3.8bn | +₩4.5bn | +$3M | ₩-18.3bn | +₩14.5bn |
| Komipharm International 코미팜 | 041960 | KOSDAQ | ₩1T ($0.6B) | 4.66% | – | +₩0.4bn | +₩2.7bn | +₩3.4bn | +$3M | ₩-0.9bn | ₩-2.5bn |
| Jwpharmaceutical JW중외제약 | 001060 | KOSPI | ₩1T ($0.4B) | 7.72% | – | +₩0.5bn | +₩0.4bn | +₩2.8bn | +$2M | +₩0.1bn | ₩-3.0bn |
| Aimed Bio 에임드바이오 | 0009K0 | KOSDAQ | ₩1T ($1.0B) | 3.03% | – | ₩-0.6bn | ₩-1.0bn | +₩2.6bn | +$2M | ₩-1.3bn | ₩-1.4bn |
| Tomocube 토모큐브 | 475960 | KOSDAQ | ₩0T ($0.3B) | 2.13% | 33.6× | +₩0.5bn | +₩1.0bn | +₩2.2bn | +$2M | +₩2.0bn | ₩-4.6bn |
| Onconic Therapeutics 온코닉테라퓨틱스 | 476060 | KOSDAQ | ₩1T ($0.5B) | 0.21% | 20.6× | +₩0.5bn | ₩-0.7bn | +₩2.2bn | +$2M | ₩-1.1bn | ₩-1.3bn |
| Samyang Biopharm 삼양바이오팜 | 0120G0 | KOSPI | ₩0T ($0.2B) | 3.37% | – | +₩0.0bn | ₩-0.5bn | +₩1.9bn | +$1M | ₩-0.6bn | ₩-1.0bn |
| Yuhan 유한양행 | 000100 | KOSPI | ₩5T ($4.0B) | 21.21% | 28.6× | +₩2.2bn | +₩10.9bn | +₩1.8bn | +$1M | ₩-19.9bn | +₩17.4bn |
| Caregen 케어젠 | 214370 | KOSDAQ | ₩2T ($1.6B) | 4.63% | – | +₩0.2bn | +₩0.3bn | +₩1.8bn | +$1M | +₩0.1bn | ₩-3.3bn |
| Pharmicell 파미셀 | 005690 | KOSPI | ₩1T ($0.5B) | 8.69% | 9.6× | +₩1.4bn | +₩3.1bn | +₩1.4bn | +$1M | +₩7.3bn | ₩-8.9bn |
| Tool Gen Incorporated 툴젠 | 199800 | KOSDAQ | ₩0T ($0.2B) | 2.84% | – | ₩-0.3bn | ₩-0.2bn | +₩1.4bn | +$1M | ₩-4.0bn | +₩2.6bn |
| SD Biosensor 에스디바이오센서 | 137310 | KOSPI | ₩1T ($0.6B) | 6.1% | – | +₩0.1bn | +₩0.0bn | +₩1.1bn | +$1M | +₩0.0bn | ₩-0.8bn |
| Vieworks 뷰웍스 | 100120 | KOSDAQ | ₩0T ($0.2B) | 30.41% | 7.1× | +₩0.2bn | +₩0.9bn | +₩0.9bn | +$1M | +₩0.1bn | ₩-1.2bn |
| Bukwang Pharmaceutical 부광약품 | 003000 | KOSPI | ₩0T ($0.3B) | 6.9% | – | ₩-0.1bn | ₩-1.5bn | +₩0.8bn | +$1M | ₩-4.4bn | +₩3.6bn |
| Ildong Pharm 일동제약 | 249420 | KOSPI | ₩0T ($0.3B) | 5.21% | – | +₩0.5bn | ₩-0.1bn | +₩0.7bn | +$1M | ₩-0.6bn | ₩-0.2bn |
| Celltrion Pharm 셀트리온제약 | 068760 | KOSDAQ | ₩2T ($1.3B) | 4.9% | 36.3× | ₩-0.7bn | +₩1.1bn | +₩0.7bn | +$1M | ₩-9.4bn | +₩8.6bn |
| JVM 제이브이엠 | 054950 | KOSDAQ | ₩0T ($0.2B) | 19.98% | 7.6× | +₩0.3bn | +₩0.7bn | +₩0.7bn | +$0M | +₩0.3bn | ₩-0.9bn |
| Hyundai pharm 현대약품 | 004310 | KOSPI | ₩0T ($0.2B) | 1.24% | – | +₩0.6bn | +₩0.1bn | +₩0.6bn | +$0M | ₩-0.0bn | ₩-0.8bn |
| HLB Life Science HLB생명과학 | 067630 | KOSDAQ | ₩0T ($0.4B) | 5.93% | – | ₩-0.7bn | +₩0.4bn | +₩0.6bn | +$0M | ₩-0.3bn | ₩-0.2bn |
| Boditech Med 바디텍메드 | 206640 | KOSDAQ | ₩0T ($0.2B) | 3.6% | – | +₩0.2bn | +₩0.7bn | +₩0.3bn | +$0M | +₩0.1bn | ₩-0.5bn |
| Medipost 메디포스트 | 078160 | KOSDAQ | ₩0T ($0.3B) | 2.52% | – | +₩0.2bn | ₩-0.1bn | +₩0.3bn | +$0M | +₩0.0bn | ₩-0.4bn |
| Prestige Biopharma Limited Kdr 프레스티지바이오파마 | 950210 | KOSPI | ₩0T ($0.2B) | 63.64% | – | +₩0.1bn | +₩0.0bn | +₩0.1bn | +$0M | +₩0.0bn | ₩-0.1bn |
| GI Innovation 지아이이노베이션 | 358570 | KOSDAQ | ₩0T ($0.4B) | 8.76% | – | ₩-0.4bn | ₩-3.7bn | +₩0.1bn | +$0M | ₩-1.0bn | +₩0.3bn |
| Dx & Vx DXVX | 180400 | KOSDAQ | ₩0T ($0.2B) | 4.89% | – | +₩0.1bn | +₩0.1bn | +₩0.0bn | +$0M | +₩0.0bn | ₩-0.1bn |
| Genomictree 지노믹트리 | 228760 | KOSDAQ | ₩0T ($0.2B) | 2.88% | – | ₩-0.4bn | +₩1.5bn | +₩0.0bn | +$0M | ₩-1.5bn | +₩1.3bn |
| It-chem 아이티켐 | 309710 | KOSDAQ | ₩0T ($0.2B) | 0% | – | ₩0.0bn | ₩0.0bn | ₩0.0bn | $0M | ₩0.0bn | ₩0.0bn |
| NK Gen Biotech Korea 엔케이젠바이오텍코리아 | 182400 | KOSDAQ | ₩0T ($0.2B) | 0% | – | ₩0.0bn | ₩0.0bn | ₩0.0bn | $0M | ₩0.0bn | ₩0.0bn |
| Bio Note 바이오노트 | 377740 | KOSPI | ₩0T ($0.4B) | 0.48% | – | +₩0.1bn | ₩-0.0bn | ₩-0.1bn | $-0M | ₩-0.0bn | +₩0.1bn |
| Samjin Pharmaceutical 삼진제약 | 005500 | KOSPI | ₩0T ($0.2B) | 3.64% | 10.9× | ₩-0.1bn | ₩-0.2bn | ₩-0.1bn | $-0M | ₩-0.1bn | +₩0.3bn |
| Ilsung Is 일성아이에스 | 003120 | KOSPI | ₩0T ($0.2B) | 0.31% | – | +₩0.0bn | +₩0.1bn | ₩-0.2bn | $-0M | +₩0.0bn | +₩0.1bn |
| GC 녹십자홀딩스 | 005250 | KOSPI | ₩0T ($0.3B) | 8.09% | – | +₩0.2bn | +₩0.2bn | ₩-0.3bn | $-0M | ₩-0.1bn | +₩0.4bn |
| Silla Jen 신라젠 | 215600 | KOSDAQ | ₩0T ($0.2B) | 2.57% | – | +₩0.1bn | +₩0.6bn | ₩-0.3bn | $-0M | ₩-0.5bn | +₩0.8bn |
| Donga ST 동아에스티 | 170900 | KOSPI | ₩0T ($0.2B) | 19.26% | 10.1× | ₩-0.1bn | ₩-0.1bn | ₩-0.4bn | $-0M | ₩-0.4bn | +₩0.5bn |
| Shinpoong Pharmaceutical 신풍제약 | 019170 | KOSPI | ₩1T ($0.4B) | 4.17% | – | +₩0.4bn | ₩-3.1bn | ₩-0.5bn | $-0M | ₩-0.9bn | +₩1.2bn |
| Bio Plus 바이오플러스 | 099430 | KOSDAQ | ₩0T ($0.2B) | 2.85% | – | ₩-0.0bn | ₩-0.4bn | ₩-0.5bn | $-0M | ₩-0.2bn | ₩-0.4bn |
| Kolon Tissue Gene 코오롱티슈진 | 950160 | KOSDAQ | ₩1T ($0.9B) | 3.93% | – | +₩0.0bn | ₩-3.0bn | ₩-0.5bn | $-0M | ₩-0.7bn | +₩1.6bn |
| Dentium 덴티움 | 145720 | KOSPI | ₩0T ($0.3B) | 13.17% | 5.6× | +₩0.1bn | ₩-0.0bn | ₩-0.5bn | $-0M | +₩3.1bn | ₩-2.5bn |
| Suheung 서흥 | 008490 | KOSPI | ₩0T ($0.2B) | 5.78% | – | ₩-0.0bn | ₩-0.4bn | ₩-0.6bn | $-0M | ₩-0.7bn | +₩1.1bn |
| Korea United Pharm 유나이티드제약 | 033270 | KOSPI | ₩0T ($0.2B) | 8.59% | 6.5× | +₩0.2bn | +₩0.2bn | ₩-0.6bn | $-0M | +₩0.0bn | +₩0.5bn |
| JS Link 제이에스링크 | 127120 | KOSDAQ | ₩1T ($0.7B) | 3.46% | – | +₩0.6bn | ₩-3.1bn | ₩-0.6bn | $-0M | +₩14.4bn | ₩-14.9bn |
| Wontech 원텍 | 336570 | KOSDAQ | ₩0T ($0.3B) | 3.18% | 7.9× | +₩0.3bn | ₩-0.5bn | ₩-0.6bn | $-0M | +₩1.5bn | ₩-0.8bn |
| INFINITT Healthcare 인피니트헬스케어 | 071200 | KOSDAQ | ₩0T ($0.2B) | 13.09% | – | +₩0.1bn | ₩-0.0bn | ₩-0.6bn | $-0M | +₩9.9bn | ₩-13.2bn |
| Jetema 제테마 | 216080 | KOSDAQ | ₩0T ($0.2B) | 2.25% | 126.2× | +₩0.1bn | ₩-0.2bn | ₩-0.7bn | $-1M | ₩-0.7bn | +₩1.4bn |
| i-SENS 아이센스 | 099190 | KOSDAQ | ₩0T ($0.4B) | 24.44% | 39.0× | +₩0.2bn | ₩-0.2bn | ₩-0.8bn | $-1M | ₩-0.0bn | +₩0.7bn |
| Hans Biomed 한스바이오메드 | 042520 | KOSDAQ | ₩0T ($0.2B) | 6.19% | 11.2× | ₩-0.6bn | ₩-2.1bn | ₩-0.8bn | $-1M | +₩2.7bn | ₩-1.7bn |
| Into Cell 인투셀 | 287840 | KOSDAQ | ₩0T ($0.2B) | 4.48% | – | +₩0.1bn | ₩-0.7bn | ₩-0.8bn | $-1M | ₩-0.3bn | +₩1.0bn |
| HEM Pharma HEM파마 | 376270 | KOSDAQ | ₩0T ($0.2B) | 0.51% | – | +₩0.2bn | ₩-0.6bn | ₩-0.8bn | $-1M | +₩0.0bn | +₩0.9bn |
| Myungin Pharm 명인제약 | 317450 | KOSPI | ₩1T ($0.4B) | 0.79% | – | ₩-0.2bn | ₩-1.0bn | ₩-0.9bn | $-1M | ₩-1.0bn | +₩2.1bn |
| Dae Hwa Pharm 대화제약 | 067080 | KOSDAQ | ₩0T ($0.2B) | 0.2% | – | ₩-0.5bn | ₩-1.5bn | ₩-0.9bn | $-1M | +₩0.1bn | +₩0.8bn |
| Kwangdong Pharmaceutical 광동제약 | 009290 | KOSPI | ₩0T ($0.2B) | 15.71% | – | +₩0.2bn | +₩0.1bn | ₩-1.0bn | $-1M | ₩-0.1bn | +₩1.0bn |
| Gc Cell 지씨셀 | 144510 | KOSDAQ | ₩0T ($0.2B) | 2.88% | – | ₩-0.1bn | ₩-0.2bn | ₩-1.0bn | $-1M | +₩0.0bn | +₩1.0bn |
| Humedix 휴메딕스 | 200670 | KOSDAQ | ₩0T ($0.2B) | 6.55% | 6.1× | +₩0.0bn | +₩0.1bn | ₩-1.0bn | $-1M | ₩-0.2bn | +₩1.3bn |
| Cosmax Bti 코스맥스비티아이 | 044820 | KOSPI | ₩0T ($0.2B) | 5.48% | – | ₩-0.1bn | +₩0.5bn | ₩-1.2bn | $-1M | +₩3.2bn | ₩-2.2bn |
| Huons 휴온스 | 243070 | KOSDAQ | ₩0T ($0.2B) | 15.69% | – | ₩-0.0bn | +₩0.0bn | ₩-1.2bn | $-1M | +₩0.1bn | +₩1.0bn |
| Eu Biologics 유바이오로직스 | 206650 | KOSDAQ | ₩0T ($0.2B) | 5.66% | – | +₩0.2bn | ₩-1.2bn | ₩-1.2bn | $-1M | ₩-0.4bn | +₩1.5bn |
| Boryung 보령 | 003850 | KOSPI | ₩1T ($0.5B) | 4.88% | 10.6× | +₩0.1bn | +₩0.3bn | ₩-1.3bn | $-1M | +₩2.5bn | ₩-1.1bn |
| Curexo 큐렉소 | 060280 | KOSDAQ | ₩0T ($0.2B) | 4.77% | 41.0× | +₩0.2bn | +₩0.1bn | ₩-1.3bn | $-1M | ₩-1.3bn | +₩2.5bn |
| S.Biomedics 에스바이오메딕스 | 304360 | KOSDAQ | ₩0T ($0.2B) | 1.71% | – | ₩-0.2bn | ₩-0.7bn | ₩-1.4bn | $-1M | +₩0.0bn | +₩1.4bn |
| Nextbiomedical 넥스트바이오메디컬 | 389650 | KOSDAQ | ₩0T ($0.2B) | 1.56% | 75.7× | ₩-0.0bn | ₩-0.5bn | ₩-1.7bn | $-1M | +₩0.6bn | +₩1.2bn |
| Stcube 에스티큐브 | 052020 | KOSDAQ | ₩0T ($0.4B) | 5.38% | – | ₩-0.0bn | ₩-0.4bn | ₩-1.7bn | $-1M | ₩-0.0bn | +₩2.0bn |
| Chongkundang 종근당 | 185750 | KOSPI | ₩1T ($0.7B) | 15.5% | 12.1× | +₩0.6bn | +₩1.6bn | ₩-1.7bn | $-1M | ₩-0.5bn | +₩2.3bn |
| Curocell 큐로셀 | 372320 | KOSDAQ | ₩0T ($0.3B) | 1.14% | – | +₩0.1bn | ₩-1.1bn | ₩-1.8bn | $-1M | ₩-0.4bn | +₩2.2bn |
| Value Added Technology 바텍 | 043150 | KOSDAQ | ₩0T ($0.2B) | 21.23% | 4.5× | ₩-0.2bn | ₩-0.8bn | ₩-2.1bn | $-2M | ₩-0.0bn | +₩1.9bn |
| Daewoong 대웅 | 003090 | KOSPI | ₩1T ($0.7B) | 4.94% | – | +₩0.1bn | ₩-0.0bn | ₩-2.3bn | $-2M | ₩-1.2bn | +₩3.4bn |
| Genome&Company 지놈앤컴퍼니 | 314130 | KOSDAQ | ₩0T ($0.2B) | 2.5% | – | ₩-0.0bn | ₩-0.6bn | ₩-2.3bn | $-2M | ₩-3.3bn | +₩7.2bn |
| Qurient 큐리언트 | 115180 | KOSDAQ | ₩1T ($0.6B) | 3.22% | – | ₩-3.2bn | ₩-4.9bn | ₩-2.5bn | $-2M | ₩-0.5bn | +₩1.8bn |
| HLB Therapeutics HLB테라퓨틱스 | 115450 | KOSDAQ | ₩0T ($0.2B) | 2.7% | – | ₩-0.0bn | ₩-1.1bn | ₩-2.5bn | $-2M | ₩-0.2bn | +₩2.4bn |
| GC Biopharma 녹십자 | 006280 | KOSPI | ₩1T ($1.1B) | 23.65% | 19.1× | ₩-0.3bn | ₩-2.0bn | ₩-2.5bn | $-2M | +₩2.3bn | ₩-1.1bn |
| Future Chem 퓨쳐켐 | 220100 | KOSDAQ | ₩0T ($0.2B) | 4.97% | – | +₩0.1bn | ₩-0.5bn | ₩-2.5bn | $-2M | ₩-2.7bn | +₩5.0bn |
| Daewoongpharmaceutical 대웅제약 | 069620 | KOSPI | ₩1T ($0.9B) | 14.6% | 6.5× | +₩1.6bn | +₩2.0bn | ₩-2.5bn | $-2M | ₩-2.9bn | +₩4.9bn |
| Hyundai Bioscience 현대바이오 | 048410 | KOSDAQ | ₩1T ($0.5B) | 6.35% | – | ₩-0.7bn | ₩-1.6bn | ₩-2.8bn | $-2M | ₩-0.6bn | +₩4.8bn |
| Bioneer 바이오니아 | 064550 | KOSDAQ | ₩0T ($0.2B) | 2.92% | – | +₩0.6bn | ₩-0.3bn | ₩-3.0bn | $-2M | +₩0.0bn | +₩2.9bn |
| HK inno.N HK이노엔 | 195940 | KOSDAQ | ₩1T ($0.8B) | 11.76% | 10.0× | ₩-0.8bn | +₩2.3bn | ₩-3.6bn | $-3M | ₩-0.8bn | +₩4.1bn |
| T&L 티앤엘 | 340570 | KOSDAQ | ₩0T ($0.3B) | 12.13% | 6.5× | +₩1.1bn | ₩-0.5bn | ₩-4.2bn | $-3M | +₩4.8bn | ₩-0.3bn |
| Medy-Tox 메디톡스 | 086900 | KOSDAQ | ₩0T ($0.3B) | 11.94% | 13.5× | +₩0.1bn | ₩-1.3bn | ₩-4.3bn | $-3M | ₩-0.1bn | +₩4.2bn |
| Hlb Pharmaceutical HLB제약 | 047920 | KOSDAQ | ₩1T ($0.4B) | 0% | – | ₩-0.6bn | ₩-4.1bn | ₩-4.6bn | $-3M | ₩-9.8bn | +₩14.5bn |
| Rokit Healthcare 로킷헬스케어 | 376900 | KOSDAQ | ₩0T ($0.3B) | 5.21% | – | ₩-0.2bn | ₩-2.0bn | ₩-4.7bn | $-3M | +₩0.1bn | +₩4.9bn |
| G2gbio 지투지바이오 | 456160 | KOSDAQ | ₩1T ($0.4B) | 5.15% | – | +₩1.2bn | ₩-4.8bn | ₩-4.7bn | $-4M | +₩2.6bn | +₩1.9bn |
| IM Biologics 아이엠바이오로직스 | 493280 | KOSDAQ | ₩0T ($0.2B) | 3.05% | – | ₩-0.6bn | ₩-1.2bn | ₩-4.9bn | $-4M | +₩0.9bn | +₩4.7bn |
| Penetrium Bio 페니트리움바이오 | 187660 | KOSDAQ | ₩0T ($0.3B) | 0.54% | – | ₩-0.4bn | +₩0.9bn | ₩-4.9bn | $-4M | ₩-0.0bn | +₩5.8bn |
| Oscotec 오스코텍 | 039200 | KOSDAQ | ₩1T ($1.0B) | 12.15% | 13.4× | ₩-0.4bn | ₩-4.4bn | ₩-6.6bn | $-5M | +₩19.2bn | ₩-12.7bn |
| Chabiotech 차바이오텍 | 085660 | KOSDAQ | ₩1T ($0.5B) | 7.27% | – | ₩-0.8bn | ₩-1.8bn | ₩-6.8bn | $-5M | +₩0.5bn | +₩6.4bn |
| Inventage Lab 인벤티지랩 | 389470 | KOSDAQ | ₩0T ($0.2B) | 9.45% | – | ₩-0.3bn | ₩-5.0bn | ₩-6.9bn | $-5M | ₩-4.4bn | +₩11.6bn |
| Livs Med 리브스메드 | 491000 | KOSDAQ | ₩1T ($0.6B) | 3.19% | – | +₩0.7bn | ₩-0.2bn | ₩-6.9bn | $-5M | ₩-4.6bn | +₩12.3bn |
| Proteina 프로티나 | 468530 | KOSDAQ | ₩0T ($0.4B) | 1.85% | – | ₩-0.8bn | ₩-3.3bn | ₩-7.5bn | $-6M | +₩17.7bn | ₩-9.3bn |
| Curiox Biosystems 큐리옥스바이오시스템즈 | 445680 | KOSDAQ | ₩1T ($0.7B) | 6.46% | – | ₩-0.6bn | ₩-6.1bn | ₩-7.7bn | $-6M | +₩5.7bn | +₩1.3bn |
| Ab Clon 앱클론 | 174900 | KOSDAQ | ₩0T ($0.4B) | 6.67% | – | +₩0.7bn | ₩-2.0bn | ₩-8.0bn | $-6M | +₩5.1bn | +₩2.2bn |
| Classys 클래시스 | 214150 | KOSDAQ | ₩2T ($1.4B) | 67.97% | 9.5× | ₩-1.4bn | ₩-2.8bn | ₩-8.3bn | $-6M | ₩-1.6bn | +₩9.4bn |
| Seers 씨어스 | 458870 | KOSDAQ | ₩1T ($0.7B) | 4.16% | 12.0× | +₩0.9bn | ₩-0.9bn | ₩-8.8bn | $-7M | ₩-0.5bn | +₩8.6bn |
| Immune Oncia Therapeutics 이뮨온시아 | 424870 | KOSDAQ | ₩0T ($0.2B) | 0.82% | – | +₩0.0bn | ₩-0.0bn | ₩-9.0bn | $-7M | ₩-4.2bn | +₩13.1bn |
| Rznomics 알지노믹스 | 476830 | KOSDAQ | ₩1T ($0.5B) | 8.42% | – | ₩-3.3bn | ₩-12.0bn | ₩-11.0bn | $-8M | ₩-6.9bn | +₩19.1bn |
| April Bio 에이프릴바이오 | 397030 | KOSDAQ | ₩0T ($0.3B) | 8.32% | – | +₩0.9bn | +₩3.9bn | ₩-13.3bn | $-10M | ₩-0.8bn | +₩13.9bn |
| Voronoi 보로노이 | 310210 | KOSDAQ | ₩2T ($1.6B) | 5.48% | – | ₩-0.6bn | ₩-7.9bn | ₩-19.3bn | $-15M | ₩-7.3bn | +₩24.0bn |
| Dong Kook Pharmaceutical 동국제약 | 086450 | KOSDAQ | ₩1T ($0.8B) | 9.62% | 11.4× | ₩-1.7bn | ₩-7.3bn | ₩-20.8bn | $-16M | +₩37.5bn | ₩-19.5bn |
| Hanmi Science 한미사이언스 | 008930 | KOSPI | ₩3T ($2.6B) | 0.81% | 19.7× | +₩1.1bn | ₩-17.3bn | ₩-22.2bn | $-17M | +₩19.8bn | +₩1.9bn |
| Lunit 루닛 | 328130 | KOSDAQ | ₩1T ($0.6B) | 7.55% | – | +₩1.2bn | ₩-2.0bn | ₩-23.2bn | $-17M | +₩8.5bn | +₩14.4bn |
| Samsung Epis Holdings 삼성에피스홀딩스 | 0126Z0 | KOSPI | ₩8T ($5.9B) | 5.09% | 24.0× | ₩-9.3bn | ₩-24.8bn | ₩-32.0bn | $-24M | ₩-2.1bn | +₩32.4bn |
| Mezzion Pharma 메지온 | 140410 | KOSDAQ | ₩2T ($1.4B) | 22.23% | – | +₩1.1bn | ₩-2.4bn | ₩-34.9bn | $-26M | ₩-0.9bn | +₩34.7bn |
| SK Biopharmaceuticals SK바이오팜 | 326030 | KOSPI | ₩6T ($4.2B) | 11.65% | 14.2× | +₩0.3bn | ₩-8.8bn | ₩-38.7bn | $-29M | ₩-6.1bn | +₩42.9bn |
| Hugel 휴젤 | 145020 | KOSDAQ | ₩2T ($1.6B) | 56.77% | 10.8× | ₩-1.2bn | +₩2.9bn | ₩-45.4bn | $-34M | ₩-8.1bn | +₩52.0bn |
| Olix Pharmaceuticals 올릭스 | 226950 | KOSDAQ | ₩2T ($1.6B) | 9.1% | – | ₩-5.6bn | ₩-35.5bn | ₩-46.7bn | $-35M | +₩71.0bn | ₩-16.2bn |
| L&c Bio 엘앤씨바이오 | 290650 | KOSDAQ | ₩2T ($1.2B) | 22.51% | 37.7× | ₩-24.3bn | ₩-35.1bn | ₩-57.1bn | $-43M | +₩1.5bn | +₩53.6bn |
| Samsung Biologics 삼성바이오로직스 | 207940 | KOSPI | ₩56T ($41.9B) | 12.92% | 25.8× | ₩-2.8bn | ₩-132.7bn | ₩-115.9bn | $-87M | ₩-89.3bn | +₩195.3bn |
| Hanmi Pharm 한미약품 | 128940 | KOSPI | ₩6T ($4.4B) | 11.66% | 25.7× | +₩15.8bn | ₩-58.6bn | ₩-116.3bn | $-87M | +₩128.3bn | ₩-10.4bn |
| Sam Chun Dang Pharm 삼천당제약 | 000250 | KOSDAQ | ₩5T ($3.7B) | 2.65% | – | ₩-1.4bn | ₩-86.3bn | ₩-122.7bn | $-92M | +₩19.1bn | +₩96.8bn |
| HLB HLB | 028300 | KOSDAQ | ₩6T ($4.4B) | 13.1% | – | ₩-1.2bn | ₩-28.4bn | ₩-181.3bn | $-136M | ₩-12.9bn | +₩192.9bn |
Positive = net buying, negative = net selling, in Korean won (₩bn) with USD at ₩1333.09/$. Flows aggregate the KRX main board and the NXT venue. Foreign ownership is KRX's foreign holdings divided by listed shares, one session behind. The group is the site's "Biotech & Pharma" classification, covering the largest companies by market cap.